{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:13:52Z","timestamp":1783574032118,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08-CA2560450"],"award-info":[{"award-number":["K08-CA2560450"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R38-CA245204"],"award-info":[{"award-number":["5R38-CA245204"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Duke Office of Physician Scientist Development Technician Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11060-025-05120-y","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T06:36:47Z","timestamp":1750055807000},"page":"199-208","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade"],"prefix":"10.1007","volume":"175","author":[{"given":"Jazlyn A.","family":"Seidel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K. S.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey K.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Komisarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Fecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sperduto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trey","family":"Mullikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Reitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2122-6650","authenticated-orcid":false,"given":"Eugene J.","family":"Vaios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"5","key":"5120_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41571-019-0320-3","volume":"17","author":"JH Suh","year":"2020","unstructured":"Suh JH et al (2020) Current approaches to the management of brain metastases. Nat Rev Clin Oncol 17(5):279\u2013299","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"5120_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356","journal-title":"N Engl J Med"},{"issue":"2","key":"5120_CR3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22(2):198\u2013211","journal-title":"Lancet Oncol"},{"issue":"21","key":"5120_CR4","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD et al (2019) Nivolumab plus ipilimumab in advanced Non-Small-Cell lung Cancer. N Engl J Med 381(21):2020\u20132031","journal-title":"N Engl J Med"},{"issue":"5","key":"5120_CR5","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.ijrobp.2023.12.002","volume":"118","author":"EJ Vaios","year":"2024","unstructured":"Vaios EJ et al (2024) Long-Term intracranial outcomes with combination dual Immune-Checkpoint Blockade and stereotactic radiosurgery in patients with melanoma and Non-Small cell lung Cancer brain metastases. Int J Radiat Oncol Biol Phys 118(5):1507\u20131518","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5120_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.radonc.2018.08.025","volume":"130","author":"EJ Lehrer","year":"2019","unstructured":"Lehrer EJ et al (2019) Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data. Radiother Oncol 130:104\u2013112","journal-title":"Radiother Oncol"},{"issue":"4","key":"5120_CR7","doi-asserted-by":"publisher","first-page":"e254347","DOI":"10.1001\/jamanetworkopen.2025.4347","volume":"8","author":"EJ Vaios","year":"2025","unstructured":"Vaios EJ et al (2025) Symptomatic necrosis with dual Immune-Checkpoint Inhibition and radiosurgery for brain metastases. JAMA Netw Open 8(4):e254347","journal-title":"JAMA Netw Open"},{"issue":"4","key":"5120_CR8","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ijrobp.2009.06.006","volume":"77","author":"BJ Blonigen","year":"2010","unstructured":"Blonigen BJ et al (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77(4):996\u20131001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5120_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1748-717X-6-48","volume":"6","author":"G Minniti","year":"2011","unstructured":"Minniti G et al (2011) Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48","journal-title":"Radiat Oncol"},{"issue":"1","key":"5120_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","volume":"118","author":"B Vellayappan","year":"2024","unstructured":"Vellayappan B et al (2024) A systematic review informing the management of symptomatic brain radiation necrosis after stereotactic radiosurgery and international stereotactic radiosurgery society recommendations. Int J Radiat Oncol Biol Phys 118(1):14\u201328","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"5120_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11060-017-2442-8","volume":"133","author":"JM Kim","year":"2017","unstructured":"Kim JM et al (2017) The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. J Neurooncol 133(2):357\u2013368","journal-title":"J Neurooncol"},{"issue":"5","key":"5120_CR12","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ijrobp.2016.08.039","volume":"96","author":"JA Miller","year":"2016","unstructured":"Miller JA et al (2016) Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 96(5):1060\u20131069","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5120_CR13","first-page":"400","volume":"7","author":"ZA Siddiqui","year":"2020","unstructured":"Siddiqui ZA et al (2020) Predictors of radiation necrosis in long-term survivors after gamma knife stereotactic radiosurgery for brain metastases. Neurooncol Pract 7(4):400\u2013408","journal-title":"Neurooncol Pract"},{"issue":"4","key":"5120_CR14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","volume":"95","author":"G Minniti","year":"2016","unstructured":"Minniti G et al (2016) Single-Fraction Versus Multifraction (3 x 9 Gy) Stereotactic Radiosurgery for Large (>\u20092\u00a0cm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. Int J Radiat Oncol Biol Phys 95(4):1142\u20131148","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"5120_CR15","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1080\/09546634.2021.1962002","volume":"33","author":"P Puri","year":"2022","unstructured":"Puri P, Cortese D, Baliga S (2022) A time series analysis of immune checkpoint inhibitor use in the united States medicare population: 2014\u20132019. J Dermatolog Treat 33(4):2004\u20132007","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"5120_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/COC.0000000000000866","volume":"44","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer EJ et al (2021) Trends in diagnosis and treatment of metastatic Cancer in the united States. Am J Clin Oncol 44(11):572\u2013579","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"5120_CR17","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond MS et al (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208(10):1989\u20132003","journal-title":"J Exp Med"},{"key":"5120_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fonc.2012.00102","volume":"2","author":"K Manda","year":"2012","unstructured":"Manda K et al (2012) Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells. Front Oncol 2:102","journal-title":"Front Oncol"},{"issue":"1076","key":"5120_CR19","doi-asserted-by":"publisher","first-page":"20170157","DOI":"10.1259\/bjr.20170157","volume":"90","author":"EJ Van Limbergen","year":"2017","unstructured":"Van Limbergen EJ et al (2017) Combining radiotherapy with immunotherapy: the past, the present and the future. Br J Radiol 90(1076):20170157","journal-title":"Br J Radiol"},{"issue":"6","key":"5120_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR et al (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14(6):365\u2013379","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"5120_CR21","doi-asserted-by":"publisher","first-page":"103620","DOI":"10.1016\/j.esmoop.2024.103620","volume":"9","author":"Y Koide","year":"2024","unstructured":"Koide Y, Kodaira T (2024) Concurrent antibody-drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials. ESMO Open 9(7):103620","journal-title":"ESMO Open"},{"issue":"12","key":"5120_CR22","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jamaoncol.2023.4492","volume":"9","author":"ES Lebow","year":"2023","unstructured":"Lebow ES et al (2023) Symptomatic necrosis with Antibody-Drug conjugates and concurrent stereotactic radiotherapy for brain metastases. JAMA Oncol 9(12):1729\u20131733","journal-title":"JAMA Oncol"},{"issue":"6","key":"5120_CR23","doi-asserted-by":"publisher","first-page":"100760","DOI":"10.1016\/j.adro.2021.100760","volume":"6","author":"GJ Kim","year":"2021","unstructured":"Kim GJ et al (2021) Outcomes in patients with 4 to 10 brain metastases treated with Dose-Adapted Single-Isocenter multitarget stereotactic radiosurgery: A prospective study. Adv Radiat Oncol 6(6):100760","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"5120_CR24","doi-asserted-by":"publisher","first-page":"e1283461","DOI":"10.1080\/2162402X.2017.1283461","volume":"6","author":"T Skrepnik","year":"2017","unstructured":"Skrepnik T et al (2017) Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. Oncoimmunology 6(3):e1283461","journal-title":"Oncoimmunology"},{"issue":"19","key":"5120_CR25","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1002\/cncr.30138","volume":"122","author":"JM Qian","year":"2016","unstructured":"Qian JM et al (2016) Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer 122(19):3051\u20133058","journal-title":"Cancer"},{"issue":"5","key":"5120_CR26","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.ijrobp.2024.01.009","volume":"118","author":"JP Layer","year":"2024","unstructured":"Layer JP et al (2024) Multicentric assessment of safety and efficacy of combinatorial adjuvant brain metastasis treatment by intraoperative radiation therapy and immunotherapy. Int J Radiat Oncol Biol Phys 118(5):1552\u20131562","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"5120_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM et al (2019) Long-Term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 37(1):52\u201360","journal-title":"J Clin Oncol"},{"issue":"1","key":"5120_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","volume":"125","author":"RJ Colaco","year":"2016","unstructured":"Colaco RJ et al (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125(1):17\u201323","journal-title":"J Neurosurg"},{"issue":"8","key":"5120_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","volume":"4","author":"AM Martin","year":"2018","unstructured":"Martin AM et al (2018) Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol 4(8):1123\u20131124","journal-title":"JAMA Oncol"},{"key":"5120_CR30","doi-asserted-by":"crossref","unstructured":"Vaios EJ et al (2023) Novel mechanisms and future opportunities for the management of radiation necrosis in patients treated for brain metastases in the era of immunotherapy. Cancers (Basel), 15(9).","DOI":"10.3390\/cancers15092432"},{"issue":"4","key":"5120_CR31","doi-asserted-by":"publisher","first-page":"101732","DOI":"10.1016\/j.adro.2025.101732","volume":"10","author":"CS Dejonckheere","year":"2025","unstructured":"Dejonckheere CS et al (2025) Boswellia serrata for the management of Radiation-Induced cerebral edema and necrosis: A systematic Meta-Narrative review of clinical evidence. Adv Radiat Oncol 10(4):101732","journal-title":"Adv Radiat Oncol"},{"key":"5120_CR32","doi-asserted-by":"crossref","unstructured":"Upadhyay R et al (2025) Boswellia Serrata for cerebral radiation necrosis after radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys","DOI":"10.1016\/j.ijrobp.2025.02.016"},{"issue":"1","key":"5120_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11060-024-04706-2","volume":"169","author":"T Kutuk","year":"2024","unstructured":"Kutuk T et al (2024) Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis. J Neurooncol 169(1):105\u2013117","journal-title":"J Neurooncol"},{"issue":"1","key":"5120_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-024-04650-1","volume":"168","author":"NN Gecici","year":"2024","unstructured":"Gecici NN et al (2024) Comparative analysis of bevacizumab and LITT for treating radiation necrosis in previously radiated CNS neoplasms: a systematic review and meta-analysis. J Neurooncol 168(1):1\u201311","journal-title":"J Neurooncol"},{"issue":"1","key":"5120_CR35","first-page":"vdad031","volume":"5","author":"M Chan","year":"2023","unstructured":"Chan M et al (2023) Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases. Neurooncol Adv 5(1):vdad031","journal-title":"Neurooncol Adv"},{"issue":"1","key":"5120_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-024-04894-x","volume":"172","author":"AP Haskell-Mendoza","year":"2025","unstructured":"Haskell-Mendoza AP et al (2025) The LITT fit in neuro-oncology: indications, imaging, and adjunctive therapies. J Neurooncol 172(1):1\u201311","journal-title":"J Neurooncol"},{"issue":"3","key":"5120_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11060-021-03790-y","volume":"153","author":"WC Newman","year":"2021","unstructured":"Newman WC et al (2021) The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. J Neurooncol 153(3):507\u2013518","journal-title":"J Neurooncol"},{"issue":"9","key":"5120_CR38","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/neuonc\/noz048","volume":"21","author":"SF Winter","year":"2019","unstructured":"Winter SF et al (2019) Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. Neuro Oncol 21(9):1118\u20131130","journal-title":"Neuro Oncol"},{"issue":"2","key":"5120_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3171\/2014.10.JNS141610","volume":"123","author":"PK Sneed","year":"2015","unstructured":"Sneed PK et al (2015) Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg 123(2):373\u2013386","journal-title":"J Neurosurg"},{"issue":"1","key":"5120_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijrobp.2013.09.051","volume":"88","author":"C Brennan","year":"2014","unstructured":"Brennan C et al (2014) A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 88(1):130\u2013136","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5120_CR41","doi-asserted-by":"publisher","first-page":"117556","DOI":"10.1016\/j.jns.2021.117556","volume":"427","author":"A Moore","year":"2021","unstructured":"Moore A et al (2021) Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors. J Neurol Sci 427:117556","journal-title":"J Neurol Sci"},{"issue":"11","key":"5120_CR42","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00066-022-01973-8","volume":"198","author":"D Bernhardt","year":"2022","unstructured":"Bernhardt D et al (2022) DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. Strahlenther Onkol 198(11):971\u2013980","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"5120_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.prro.2022.10.013","volume":"13","author":"D Grishchuk","year":"2023","unstructured":"Grishchuk D et al (2023) ISRS technical guidelines for stereotactic radiosurgery: treatment of small brain metastases (=1\u00a0cm in Diameter)<\/at. Pract Radiat Oncol 13(3):183\u2013194","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"5120_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","volume":"12","author":"V Gondi","year":"2022","unstructured":"Gondi V et al (2022) Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol 12(4):265\u2013282","journal-title":"Pract Radiat Oncol"},{"issue":"20","key":"5120_CR45","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1200\/JCO.22.00333","volume":"40","author":"D Schiff","year":"2022","unstructured":"Schiff D et al (2022) Radiation therapy for brain metastases: ASCO guideline endorsement of ASTRO guideline. J Clin Oncol 40(20):2271\u20132276","journal-title":"J Clin Oncol"},{"issue":"8","key":"5120_CR46","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","volume":"21","author":"R Kotecha","year":"2019","unstructured":"Kotecha R et al (2019) The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro Oncol 21(8):1060\u20131068","journal-title":"Neuro Oncol"},{"issue":"28","key":"5120_CR47","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC et al (2018) Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed Death-Ligand 1 Blockade in patients with Non-Small-Cell lung Cancer. J Clin Oncol 36(28):2872\u20132878","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05120-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05120-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05120-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:08:50Z","timestamp":1757196530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05120-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["5120"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05120-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Duke University Health System IRB Research Ethics Committee validated that no approval for the study of human subjects was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was IRB approved, and no consent was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"No individual data was published in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Z.J.R. reported holding a patent for brain tumor diagnostic tests with royalties paid for Genetron Health and managed by Duke University and receiving honoraria for lectures from Eisai Pharmaceuticals and Oakstone Publishing outside the submitted work. E.J.V. reported receiving grants from the National Institutes of Health\/National Cancer Institute (NIH\/NCI) (5R38-CA245204 and 1K38CA292995-01), Duke University Office of Physician Scientist Development, American Cancer Society, and Duke Cancer Institute P30 Cancer Center Support Grant (NIH\/NCI CA014236) during the conduct of the study. E.J.V reported receiving consulting fees from Elsevier Pharmaceuticals LLC and Glasshouse Health. T.M. reported receiving personal fees from Telix Pharmaceuticals and Janssen Pharmaceuticals outside the submitted work. J.P.K. reported being an owner of ClearSight RT and receiving grants from LadeRx outside the submitted work. S.R.F. reported receiving grants from NIH\/NCI during the conduct of the study and serving on the board of directors as well as owning stock in Round Table Research outside the submitted work. P.E.F. reported serving as a consultant for Monteris Medical. A.K.S reported serving as a consultant for Bristol Myers Squibb, Iovance Biotherapeutics, Regeneron, Novartis, and Pfizer. A.K.S received funding paid to the institution from Ascentage Pharma, Bristol Myers Squibb, IDEAYA Biosciences, Immunocore Holdings plc, Merck & Co, Olatec Therapeutics, Regeneron Pharmaceuticals, Replimune Group, and Seagen outside the submitted work. No other disclosures were reported.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}